Acadian Asset Management LLC Has $14.91 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Acadian Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 1.3% in the first quarter, Holdings Channel reports. The institutional investor owned 853,896 shares of the biotechnology company’s stock after purchasing an additional 10,952 shares during the period. Acadian Asset Management LLC’s holdings in Enanta Pharmaceuticals were worth $14,906,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in Enanta Pharmaceuticals by 417.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,281 shares in the last quarter. Strs Ohio raised its stake in shares of Enanta Pharmaceuticals by 20.6% in the fourth quarter. Strs Ohio now owns 18,700 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 3,200 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new position in Enanta Pharmaceuticals in the first quarter worth $118,000. Quest Partners LLC acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth $146,000. Finally, Diversified Trust Co bought a new stake in Enanta Pharmaceuticals in the 4th quarter valued at $159,000. Institutional investors own 94.99% of the company’s stock.

Wall Street Analyst Weigh In

ENTA has been the subject of a number of analyst reports. JMP Securities reduced their price objective on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a report on Tuesday, May 7th. HC Wainwright lowered their price objective on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th. Finally, StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $19.00.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA traded down $0.39 during mid-day trading on Friday, hitting $14.32. 104,547 shares of the stock were exchanged, compared to its average volume of 212,957. Enanta Pharmaceuticals, Inc. has a twelve month low of $8.08 and a twelve month high of $20.04. The stock’s fifty day simple moving average is $13.08 and its two-hundred day simple moving average is $13.52. The company has a market cap of $303.30 million, a P/E ratio of -2.29 and a beta of 0.60.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.21). The business had revenue of $17.05 million for the quarter, compared to analyst estimates of $16.47 million. Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative return on equity of 64.85%. As a group, equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -5.95 earnings per share for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the sale, the insider now owns 21,717 shares in the company, valued at approximately $370,926.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Tara Lynn Kieffer sold 7,266 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $12.33, for a total transaction of $89,589.78. Following the transaction, the insider now owns 32,341 shares of the company’s stock, valued at $398,764.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the sale, the insider now owns 21,717 shares of the company’s stock, valued at $370,926.36. The disclosure for this sale can be found here. Insiders sold 16,940 shares of company stock valued at $246,181 over the last ninety days. 13.64% of the stock is owned by insiders.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.